Biogen Reports Positive Pediatric EMPAVELI Data in C3G
CAMBRIDGE, Mass. — September 17, 2026 Biogen announced publication of prespecified adolescent subgroup results from the Phase 3 VALIANT...
Biogen
Advertisement
Kali Therapeutics Wins FDA Clearance for KT501 IND
San Mateo, California, USA, September 3, 2026 Kali Therapeutics announced that the U.S. Food and Drug Administration (FDA) has...
Eisai and Biogen Win China Approval for LEQEMBI SC
Tokyo, Japan and Cambridge, Massachusetts, USA, September 3, 2026 Eisai Co., Ltd. and Biogen Inc. announced that China’s National...
Stoke Therapeutics and Biogen Report 4-Year Data Supporting Zorevunersen’s Potential in Dravet Syndrome
Bedford, Massachusetts, USA September 3, 2026 Stoke Therapeutics and Biogen have presented new long-term clinical data supporting the potential...
Stoke Therapeutics and Biogen Present Zorevunersen Data at EEC
ATHENS, Greece, September 1, 2026 Stoke Therapeutics and Biogen announced presentations of clinical data supporting the potential of zorevunersen,...
Advertisements
Eisai and Biogen Advance LEQEMBI Access in Canada
TOKYO and CAMBRIDGE, Mass., August 31, 2026 Eisai and Biogen announced that Canada’s Drug Agency (CDA-AMC) has issued a...
Eisai and Biogen Launch LEQEMBI IQLIK for Alzheimer’s
Tokyo, Japan and Cambridge, Massachusetts, August 25, 2026 Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI IQLIK® (lecanemab-irmb)...
Biogen Shares Positive Alzheimer’s Trial Results
CAMBRIDGE, Mass., July 14, 2026 Biogen announced positive Phase 2 CELIA study results demonstrating that investigational antisense oligonucleotide therapy...
Eisai Advances Alzheimer’s Care with LEQEMBI IQLIK Approval
TOKYO, Japan & CAMBRIDGE, Mass., July 13, 2026 Eisai Co., Ltd. and Biogen Inc. have achieved a major regulatory...
GSK and Spero Secure FDA Nod for First Oral Carbapenem
LONDON, United Kingdom, June 18, 2026 GSK plc and Spero Therapeutics have achieved a major milestone in the fight...
Advertisement
